NCT02128724View on ClinicalTrials.gov

Palliative Thoracic Radiotherapy Plus BKM120

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

October 17, 2017

Study Completion Date

October 17, 2017

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

BKM120

Buparlisib is a highly specific inhibitor of phosphatidylinositol 3-kinase (PI3K). Buparlisib is supplied as 10mg and 50mg hard gelatin capsules.

Trial Locations (1)

OX3 7LE

Churchill Hospital, Oxford

Sponsors
All Listed Sponsors
collaborator

Cancer Research UK

OTHER

collaborator

Novartis

INDUSTRY

lead

University of Oxford

OTHER